首页> 外文期刊>BMC Complementary and Alternative Medicine >A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen? dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis
【24h】

A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen? dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis

机译:对Calmagen进行的单中心,双盲,安慰剂对照,随机,平行研究的试点?皮肤药膏和乳液用于局部治疗癣和灰指甲

获取原文
           

摘要

Background Most of the current anti-fungal treatments are chemical-based, fungistatic, have low efficacy in the treatment of tinea and toxicity concerns, while onychomycosis remains recalcitrant to most antifungal therapies. The study aimed to establish the fungicidal, efficacy and safety profile of Calmagen? dermaceutical cream and lotion containing AMYCOT? as a topical treatment in patients with severe to very severe presentations of fungal skin (tinea) and nail infections (onychomycosis). Methods A randomized, placebo-controlled, double blind, parallel, single centre study was conducted on 28 subjects with severe to very severe tinea or onychomycosis. All patients were randomized in a ratio of 1:1 for treatment or placebo group. Subjects in the treatment arm received Calmagen? cream or lotion, while subjects in the placebo arm received a similar inert topical preparation. Tinea subjects were treated with cream for four weeks, while onychomycosis subjects were treated with lotion for 12?weeks. Mycological cure, the primary endpoint, was assessed by three parameters: KOH (potassium hydroxide) smear, fungal culture and live spore count. Clinical cure was defined as Investigator Global Assessment (IGA) response of ‘cleared’ or ‘excellent’. Results All three parameters constituting mycological cure were confirmed in 92.8% (13/14) of subjects in the treatment arm, while all 14 subjects in the placebo arm remained positive for KOH smear. Calmagen? cream and lotion treatment showed a significant improvement in all three parameters: KOH smear, (95% CI (Calmagen): 79.4, 100.0; 95% CI (placebo): 0.0, 0.0; p p p Conclusions The Calmagen? cream and lotion containing AMYCOT? represent a potentially safe and efficacious natural alternative in the treatment of Tinea and onychomycosis. Trial registration This trial has been registered with the clinical trial registry-India (CTRI; registration number: CTRI/2012/03/002522 ).
机译:背景技术当前大多数抗真菌治疗是基于化学的,抑真菌的,在治疗体癣和毒性方面的功效较低,而灰指甲病对大多数抗真菌治疗仍然是顽固的。该研究旨在确定卡尔马根的杀菌,功效和安全性。含有AMYCOT的护肤霜和乳液?在有严重到非常严重的真菌皮肤(癣)和指甲感染(甲癣)表现的患者中作为局部治疗。方法对重度至非常重的癣或灰指甲的28名受试者进行了一项随机,安慰剂对照,双盲,平行,单中心研究。所有患者均以1:1的比例随机分配至治疗组或安慰剂组。治疗组中的受试者接受了Calmagen?乳霜或乳液,而安慰剂组的受试者也接受了类似的惰性局部用药。头晕类科目接受乳膏治疗4周,灰指甲病科目接受洗液治疗12周。真菌学治愈(主要终点)通过三个参数进行评估:KOH(氢氧化钾)涂片,真菌培养和活孢子计数。临床治愈被定义为研究人员全球评估(IGA)对“明确”或“优秀”的回应。结果在治疗组中,有92.8%(13/14)的受试者确认了构成真菌学治愈的所有三个参数,而在安慰剂组中的所有14名受试者仍保持KOH涂片阳性。卡尔马根?霜和洗剂的处理在所有三个参数上均显示出显着改善:KOH涂片,(95%CI(Calmagen):79.4,100.0; 95%CI(安慰剂):0.0,0.0; ppp)结论含有AMYCOT?的Calmagen?霜和洗剂。试验注册该试验已在印度临床试验注册中心进行了注册(CTRI;注册号:CTRI / 2012/03/002522)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号